Skip to main content

GlaxoSmithKline

 

Clinical courses

  • Worlds poor to get pneumonia vaccines at affordable cost

    In a novel agreement, two global pharma majors have planned to make available their top-selling pneumonia vaccines at one-eighth of the market rates to save lives of poor children in developing countries.

    Every day, 4,384 people, mostly children below the age of five, die due to preventable pneumococcal diseases, primarily pneumonia and meningitis. Most of these deaths, 1.6 million in a year, occur in some of the world’s poorest countries.

  • GSKs CAT to help COPD patients better manage their chronic lung disease

    Singapore, Mar 30, 2010: A new and simple test to help patients cope better with COPD, a chronic lung disease is being launched to local medical practitioners of Singapore. Experts now hope the COPD Assessment Test (CAT) that was funded by GlaxoSmithKline (GSK) and is freely available for use, will be a significant breakthrough in efforts to reduce the burden of one of the world’s most debilitating diseases.

  • FDA Temporarily Suspends Use of Rotarix Vaccine

    March 22, 2010 — The US Food and Drug Administration (FDA) announced today viral contamination of GlaxoSmithKline's Rotarix vaccine. The agency is recommending that doctors stop using the vaccine until further investigations are complete.

    An independent academic research team testing the product recently identified porcine circovirus 1 in the vaccine and notified regulators.

Subscribe to GlaxoSmithKline